Two glycoforms of a secretable human thrombomodulin mutant [TMDl-105 and TMDl-75; Parkinson, Grinnell, Moore, Hoskins, Vlahos & Bang (1990) thrombomodulin and lies within a sequence Ser-Gly-Ser-Gly-Glu-Pro, which has strong similarity to chondroitin sulphate attachment sites in other proteoglycans. Five peptides with N-linked carbohydrate were also isolated and contained glycosylation sites in the lectin-like domain (Asn-47, Asn-1 15, Asn-1I16) and in the fourth (Asn-382) and fifth (Asn-409) epidermal growth factor domains. The role of N-linked and simple 0-linked carbohydrates in the functions of human thrombomodulin remain unclear. The present studies demonstrate, however, that the presence of chondroitin sulphate in human thrombomodulin has profound effects on all of the anticoagulant properties of this important anticoagulant thrombin receptor.
INTRODUCTION
Thrombomodulin (TM) plays a pivotal role in haemostasis by regulating the macromolecular specificity of thrombin at the endothelial-cell surface (Esmon, 1989) . Formation of a highaffinity thrombin-TM complex accelerates the rate of thrombindependent formation of activated protein C and also directly inhibits thrombin's procoagulant activities (Esmon & Owen, 1981; Esmon et al., 1983) .
Expression of a secretable deletion mutant of human TM in human 293 and Syrian-hamster AV12 cells was recently reported (Parkinson et al., 1990a) . This mutant contained all of the extracellular domains of TM and was secreted as two discrete glycoforms of approx. 105 kDa and approx. 75 kDa . The functional properties of and TMDI-75 differed with respect to cofactor activity for protein C activation, Ca2l-dependence and inhibition of thrombin's procoagulant activities. These observations were the first report of a critical role for glycosylation in the functions of human TM. Preliminary evidence indicated that TMDI-105 contained a chondroitin sulphate glycosaminoglycan (CSGAG) whereas TMD1-75 did not. Results similar to those described above were confirmed by an independent study that showed the presence of chondroitin 4-sulphate in a secretable mutant of human TM expressed in Chinese-hamster ovary cells (Nawa et al., 1990) . A series of elegant studies with rabbit TM had previously shown a significant role for CSGAG in inhibiting thrombin's procoagulant activities and in accelerating the rate of thrombin inhibition by antithrombin III (Bourin, 1989; Bourin et al., 1988 Preissner et al., 1987 Preissner et al., , 1990 .
The present studies investigated the relationship between TMDI-105 and TMDI-75 at the carbohydrate level in more detail. This was done in order to identify carbohydrate structures other than CSGAG that could account for the functional differences between the two glycoforms. The only difference in glycosylation between the two glycoforms that was identified was the presence of CSGAG in and the absence of CSGAG from . The site of CSGAG attachment in TMDI-105 was localized to the 0-glycosylation domain immediately C-terminal to the primary thrombin-binding site in epidermal growth factor domains 5 and 6. The results indicate that the presence of CSGAG in the 0-glycosylation domain of human TM can regulate all the anticoagulant functions of this important thrombin receptor.
MATERIALS AND METHODS Materials
Recombinant and TMDI-75 expressed in human 293 cells were purified as described previously (Parkinson et al., 1990a) . Bovine thrombin (2400 N.I.H. units/mg) was from Enzyme Research Laboratories (South Bend, IN, U.S.A.). Recombinant human protein C was purified as previously described (Grinnell et al., 1987 Co. (Indianapolis, IN, U.S.A.) . Unless otherwise stated, all other reagents were of highest purity commercially available.
Metabolic labelling of TMD1
A stable human 293 cell transformant expressing recombinant TMD1 was maintained in Dulbecco's modified Eagle's medium containing 10 % (v/v) fetal-calf serum, 50,ug of gentamicin/ml and 200,ug of hygromycin/ml. The line was grown to confluence in a roller bottle and 100 ml serum-free medium collections were obtained daily as described previously (Parkinson et al., 1990a) . Serum-free medium contained 5 ,Ci of [3H]glucosamine/ml and 10 1sCi of [35S]sulphate/ml as precursors for N-/O-linked carbohydrate and sulphated glycosaminoglycans respectively. Labelled recombinant TMD1-105 and TMD1-75 were purified from 1 litre of serum-free medium as described previously (Parkinson et al., 1990a) .
Reduction and carboxymethaylation
Samples of TMDI-105 or TMDI-75 in 0.5 ml of 6 M-guanidinium hydrochloride/20 mM-Tris/HCl buffer, pH 8.5, were reduced by incubation with 5 % (v/v) 2-mercaptoethanol for 2 h at room temperature. Samples were then treated with 50Sl of vinylpyridine for 1.5 h in the dark, acidified with 2001ul of 70 % (v/v) formic acid and buffer-exchanged with the use of Centricon-30 microconcentrators (Amicon, Lexington, MA, U.S.A.).
Carbohydrate analysis
Reduced and carboxymethylated samples of TMDI-105 and TMDI-75 were desalted into 50 mM-ammonium bicarbonate, freeze-dried and resuspended in water. Sialic acid (N-acetylneuraminic or N-acetylglycollylneuraminic acid) released by neuraminidase and neutral/basic monosaccharides released by trifluoroacetic acid hydrolysis were analysed by high-pH anionexchange h.p.l.c. with the use of pulsed amperometric detection as described previously (Yan et al., 1990) . Sialic acid yields from 2 h and 4 h digests were within 5 % of each other and the average for the two experiments was taken. Yields of other monosaccharrides were taken as the average of duplicates after hydrolysis with 2 M-trifluoroacetic acid for 6 h. Glycosyl content was determined as mol/mol of protein by using a calculated molecular mass of 52 kDa for both and TMDl-75. Previous studies showed that both glycoforms had the same sequence and composition, consistent with a polypeptide comprising residues Ala-19-Ser-515 (Parkinson et al., 1990a) .
Chondroitin lyase digestions
For SDS/PAGE and cofactor activity studies, samples of TMDI-105 and TMDl-75 (75 ug in 1 ml) were digested with or without 200 milliunits of chondroitin ABC lyase as described previously (Parkinson et al., 1990a) . For gel-filtration analysis, samples of labelled (1 x 106 total c.p.m.) and (0.34 x 106 total c.p.m.) were incubated with and without 50 milliunits of chondroitin ABC lyase in a total volume of 0.5 ml. Superose-6 gel-filtration analyses of 0.2 ml portions from each incubation were performed as described previously (Parkinson et al., 1990a with the use of silver-stained 10-15 % gradient Phastgels (Pharmacial/LKB) as described previously (Parkinson et al., 1990a) .
Protein assays
Protein assays were performed with the bichinconinic acid assay reagent kit (Pierce Chemical Co., Rockford, IL, U.S.A.), with BSA as standard.
RESULTS
Carbohydrate composition of TMD1-105 and TMD1-75 Table 1 summarizes the glycosyl contents of TMDI-105 and TMDI-75. The results confirmed that the extracellular domains of TM were extensively glycosylated. Except in the case of galactosamine, the glycosyl contents of the two glycoforms were essentially identical. The presence of galactose and sialic acid in both glycoforms is indicative of complex-type N-linked carbohydrates.
The high yield of galactosamine from TMDI-105 compared with that of TMD1-75 (29.1 and 4.9 mol/mol of protein respectively) is consistent with the presence in TMDI-105 of a galactosaminoglycan that is absent from TMDI-75. However, some caution is needed in the interpretation of these findings. The repeating disaccharide unit ofchondroitin sulphate dermatan sulphate polymers comprises N-acetylgalactosamine linked to either glucuronic acid or iduronic acid (Conrad, 1989 1 and 7) . The band at approx. 75 kDa (lanes 3-5) is marked with an asterisk to distinguish it from proteins in the chondroitin lyase preparation that was run as a control (lane 6).
with chondroitin lyase: all the 3H and 35S radioactivity was recovered in the same fractions as undigested material (see panels a and b). 35S in TMDI-75 was not released by chondroitin lyase, suggesting the presence of sulphated sugars distinct from CSGAG. The absence of low-molecular-mass products from the digest of TMDI-75 suggested that the chondroitin ABC lyase preparation used was not contaminated with non-specific glycosidases and that the digest conditions used did not lead to proteolysis. For (Parkinson et al., 1990a) . Fig. 3 shows the effects of chondroitin lyase digestion on the Ca2+-dependence of TMDI-105 and TMD1-75 cofactor activity. The Ca2+-dependence of TMD1-75 was unaffected by chondroitin lyase digestion. In contrast, a dramatic change in the Ca2+-dependence of TMD1-105 was seen after chondroitin lyase digestion. Digested TMD1-105 had a Ca2+-dependence virtually identical with that of TMD1-75.
Glycosaminoglycan-attachment site in TMD1-105
Given the critical role of CSGAG in the functions of human TM, attempts were made to identify the site of CSGAG attachment. Labelled TMD1-105 was digested with Tos-PheCH2Cl trypsin, and Mono-Q anion-exchange chromatography was used to separate acidic CSGAG-containing peptides from unglycosylated peptides and peptides containing other carbohydrate structures. This chromatogram is shown in Fig. 4 . Two peaks, one in the breakthrough and one eluted at approx. 0.5 MNaCI, contained 3H but no 35S. A third peak was eluted by stepping the gradient from 1 M-to 2 M-NaC1, and this contained over 95 % of the 35S radioactivity and most of the 3H radioactivity. The high recovery of 'H radioactivity in this peak suggested that the isolated CSGAG-containing peptides contained carbohydrates additional to CSGAG.
The isolated CSGAG-containing peptides were desalted, Concn. of Ca2, (mM) Ser-492 in peptide 2 was a blank cycle, indicating that this residue was glycosylated.
Identification of N-linked glycosylation sites in TMD1-105 An h.p.l.c. tryptic peptide map of labelled TMD I -105 is shown in Fig. 5 . In addition to the breakthrough peak, which contained most of the 3H radioactivity (essentially all the 35S radioactivity was also recovered in this peak), five 3H-containing peptides were identified. These peptides were sequenced and identified as follows: peptide 1, Ala-372-Asn-382 (N-linked sugar at Asn-382); peptide 2, Gly-106-Tyr-1 19 (N-linked sugar at either Asn-115 or Asn-116); peptide 3, Ala372-Ala392 (N-linked sugar at Asn-382); peptide 4, Ala-37-Ile-51 (N-linked sugar at Asn-47); peptide 5, Cys-404-Ala-423 (N-linked sugar at Asn-409). In peptides 1, 3, 4 and 5, blank cycles were seen for the N-linked asparagine residues. In the case of peptide 2, asparagine was present at low amounts in the sequencing cycles corresponding to residues Asn-1 15 and Asn-116, suggesting that TMD1-105 was produced as a mixture of proteins partially glycosylated at both these sites. Peptides I and 3 were most probably the results of diffetential C-terminal tryptic cleavage. Peptide 2 resulted from tryptic cleavage of a Phe-Ala bond. Such a cleavage is unusual, -but has been observed previously (Kriauciunas et al., 1991; C. J. Vlahos, unpublished work).
Vol. 283 DISCUSSION An extensive study of the functional properties of TMD1-105 and TMD1-75 was previously reported (Parkinson et al., 1990a) . The two glycoforms differed with respect to Kd for thrombin, kca. for thrombin-dependent protein C activation and Ca2+-dependence for protein C activation. They also differed in their ability to directly inhibit thrombin's procoagulant activities, e.g. fibrinogen cleavage and platelet activation. This latter activity was considerably higher for TMD1-105 than for TMD1-75, and only TMD1-105 was sensitive to digestion with chondroitin ABC lyase.
In the present studies, attempts to identify carbohydrate structures other than CSGAG that could account for the functional differences between the two glycoforms were unsuccessful. The only difference in glycosylation between TMD1-105 and TMDI-75 that could be identified was the presence of CSGAG in TMD1-105. This was corroborated by both glycosyl content analysis and by chondroitin lyase digestion of labelled proteins. The results also showed that the biochemical and functional properties of TMD1-105 were converted into those of TMD1-75 simply by digestion with chondroitin ABC lyase. This forces the conclusion that all of the functional differences between the two glycoforms can be accounted for by CSGAG. Studies with rabbit TM showed that CSGAG was involved in inhibition of thrombin's procoagulant activities and acceleration of thrombin inhibition by antithrombin III, but not in protein C activation by the thrombin-TM complex (Bourin et al., 1988 Bourin, 1989) . These studies did not examine, however, the Ca2+-dependence of protein C activation as is described here. Removal of CSGAG from TMDI-105 clearly converted the Ca2+-dependence of protein C activation into that of TMD1-75. This regulatory role of CSGAG in protein C activation by the thrombin-TM complex has previously been overlooked and suggests a much wider role for CSGAG in regulation of the functions of the thrombin-TM complex than had previously been appreciated.
Subtraction of the glucosamine content of TMD1-75 from that of TMDI-105 gives a conservative estimate of an average CSGAG chain length of 25 disaccharide units/molecule of TMDI-105. It is not surprising that a highly anionic sulphated polysaccharide of this size would have major effects on the functions of the thrombin-TM complex. Electrostatic interactions in a ternary complex of thrombin, TM and protein C would be expected to be profoundly affected by such a structure.
X-ray crystallography of thrombin has shown several surface clusters of positively charged residues along an extended groove, distant from the active site (Bode et al., 1989; Rydel et al., 1990 ). This groove, often referred to as the 'anion-binding exosite', is a determinant of thrombin's substrate-specificity. Electrostatic interaction between positively charged surfaceloops in the exosite (or possibly other sites) of thrombin and the negatively charged CSGAG chain of TMD1-105 may account for the higher thrombin affinity of TMDI-105 (Kd approx. 3 nM) than TMDl-75 (Kd approx. 16 nM). By binding to the exosite region of thrombin, CSGAG would act as both a steric and an electrostatic impediment to interaction of thrombin with its procoagulant substrates and platelet/endothelial receptors. Absence of CSGAG, as in TMDI-75, would result in a lower-affinity thrombin-TM complex and allow for interaction of thrombin's substrates or receptors with the exosite. This would explain the marked difference in the abilities of TMD I -105 and TMD1-75 to inhibit thrombin's procoagulant activities and to inhibit thrombin-stimulated platelet activation (Parkinson et al., 1990a) .
Interaction between the y-carboxyglutamic acid-containing (Gla) domain of protein C and the epidermal growth factor repeats of TM via a Ca2+ bridge has been suggested (Kurosawa et al., 1987) . CSGAG present in the 0-glycosylation domain of TMD1-105 may cause charge repulsion of the negatively charged Gla domain of protein C. The 10-fold higher Ca2+ optimum of TMD1-105(3 mM) compared with TMD1-75 (0.3 mM) may reflect additional Ca2+ ions required to neutralize this charge repulsion effect of CSGAG and to allow the formation of the Ca2' bridge between the two proteins. Such a mechanism is consistent with the effects of chondroitin lyase on the Ca2+-dependency of TMD1-105, as discussed above.
Because of the complexity of glycosylation in the 0-glycosylation domain of TMDI-105, the location of CSGAG attachment could not be unequivocally identified. CSGAG attachment in proteoglycans typically occurs via a xylose 0-linked to serine in sequences containing Ser-Gly repeats (Bourdon et al., 1987) . The tetrapeptide sequence Ser-490-Gly-493 was proposed as a potential site of CSGAG attachment in human TM (Bourin et al., 1988) , and was present in both CSGAG-containing peptides isolated in this study. The data obtained for these peptides indicated that Ser-492 was glycosylated but Ser-490 was not. It is noteworthy that Ser-492 is conserved in the human, bovine and mouse TM genes, whereas Ser-490 is not (Wen et al., 1987; Jackman et al., 1986; Dittman et al., 1988) . The site of CSGAG attachment in TMD1-105 can thus be conditionally assigned to Ser-492. More detailed peptide mapping studies and/or sitespecific mutagenesis of the 0-glycosylation sites in this domain will be required for confirmation of this assignment.
The present study identified N-glycosylation sites in TMD1-105 at Asn-47, Asn-382 and Asn-409. These sites all conform to the N-glycosylation consensus sequence and were predicted from earlier molecular-biology studies (Wen et al., 1987) . It was difficult to assign glycosylation at Asn-115 and Asn-116 because small quantities of asparagine were seen in the sequencing cycles corresponding to each of these residues rather than the expected blank cycles. The data suggest that TMDI-105 expressed in human 293 cells was partially glycosylated at both these sites. Further studies will be required to confirm this finding. The amino acid sequence in this region, Thr-Gly-Asp-Asn-Asn-ThrSer, does not appear to favour one asparagine residue over the other for N-glycosylation. The nature and function of the carbohydrate chains present at the sites described above were not studied. Asn-47, Asn-115 and Asn-116 all lie within the Nterminal domain of TM. The function of this domain is not known, but it has sequence similarity to lectin-like domains in other proteins (Patthy, 1988) . The presence of TM at cell-cell interfaces in non-vascular tissues has led to the suggestion that the lectin domain may confer TM with carbohydrate-dependent adhesive properties involved in cell-cell interactions (Imada et al., 1990) . The function of the carbohydrate at Asn-409 is not known, but this site is conserved and also glycosylated in the fifth epidermal growth factor domain of rabbit TM and is thus at or near the primary thrombin-binding site (Stearns et al., 1988) . Removal of this carbohydrate by digestion with N-Glycanase, however, did not appear to effect thrombin binding. The function of this carbohydrate and that at Asn-382 in the fourth epidermal growth factor domain are thus not known.
The present studies clearly demonstrate the presence and dramatic functional significance of CSGAG in the extracellular domains of human TM. The presence of CSGAG in native human endothelial-cell TM, either in culture or in vivo, remains controversial (Dittman & Majerus, 1990) . Human TM purified from placenta had a molecular mass of approx. 105 kDa and did not appear as a diffuse band on SDS/PAGE, as would be expected for aprotein modified with heterogeneous CSGAG (Salem et al., 1984) . Moreover, human placental TM was a poor inhibitor of thrombin's procoagulant activities (Maruyama et al., 1985) , and in this regard resembled TMD1-75 and not TMD1-105. There is thus no evidence that native human TM is modified by CSGAG. In these earlier studies, however, the placental TM was eluted from anion-exchange columns at low ionic strength (below 0.5 M-NaCI), and in fact 80 % of cofactor activity was lost in this step. Recombinant human TM that is modified with CSGAG is eluted from anion-exchange resins at high arnionic strength (> 1.0 M-NaCl; Parkinson et al., 1990a) . The high losses of cofactor activity described in the earlier studies could be explained by placental TM modified with CSGAG not having been eluted from the anion-exchange columns with the low-ionic-strength gradients used. Indirect evidence for the presence of CSGAG on human endothelial-cell TM has been obtained (Parkinson et al., 1990b) . Cell-surface TM showed decreased affinity for thrombin following treatment of human endothelial-cell cultures with /J-D-xyloside, an inhibitor of CSGAG attachment to proteoglycans, suggesting that cultured human endothelial cells do possess TM that is modified by CSGAG.
The studies described above and those presented here suggest that the presence of CSGAG in human TM in vivo should be reinvestigated since it is clear that the presence of this carbohydrate has profound effects on TM function. The analytical techniques described in the present studies, particularly metabolic labelling, have permitted identification of all of the glycosylation sites in the extracellular domains of human TM and could be used to resolve this issue. Finally, the present studies indicate that human TM should be considered as a 'part-time' proteoglycan, raising the possibility that tissue-specific regulation of TM glycosylation (e.g. addition of CSGAG) may be a mechanism for regulation of the protein C anticoagulant pathway and the anticoagulant properties of the endothelial-cell surface.
